Analyzing the synergistic adverse effects of BPA and its substitute, BHPF, on ulcerative colitis through comparative metabolomics

Chemosphere ◽  
2022 ◽  
Vol 287 ◽  
pp. 132160
Author(s):  
Feiying Yin ◽  
Xue Huang ◽  
Xiao Lin ◽  
Ting Fung Chan ◽  
Keng Po Lai ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Adverse Effects ◽  
Comparative Metabolomics

Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?

2020 ◽  
Vol 15 (3) ◽  
pp. 216-233 ◽  
Author(s):  
Maliha Naseer ◽  
Shiva Poola ◽  
Syed Ali ◽  
Sami Samiullah ◽  
Veysel Tahan
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Clinical Trials ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Adverse Effects ◽  
Bowel Disease ◽  
Relapse Prevention ◽  
Remission Induction ◽  
Inflammatory Bowel

The incidence, prevalence, and cost of care associated with diagnosis and management of inflammatory bowel disease are on the rise. The role of gut microbiota in the causation of Crohn's disease and ulcerative colitis has not been established yet. Nevertheless, several animal models and human studies point towards the association. Targeting intestinal dysbiosis for remission induction, maintenance, and relapse prevention is an attractive treatment approach with minimal adverse effects. However, the data is still conflicting. The purpose of this article is to provide the most comprehensive and updated review on the utility of prebiotics and probiotics in the management of active Crohn’s disease and ulcerative colitis/pouchitis and their role in the remission induction, maintenance, and relapse prevention. A thorough literature review was performed on PubMed, Ovid Medline, and EMBASE using the terms “prebiotics AND ulcerative colitis”, “probiotics AND ulcerative colitis”, “prebiotics AND Crohn's disease”, “probiotics AND Crohn's disease”, “probiotics AND acute pouchitis”, “probiotics AND chronic pouchitis” and “prebiotics AND pouchitis”. Observational studies and clinical trials conducted on humans and published in the English language were included. A total of 71 clinical trials evaluating the utility of prebiotics and probiotics in the management of inflammatory bowel disease were reviewed and the findings were summarized. Most of these studies on probiotics evaluated lactobacillus, De Simone Formulation or Escherichia coli Nissle 1917 and there is some evidence supporting these agents for induction and maintenance of remission in ulcerative colitis and prevention of pouchitis relapse with minimal adverse effects. The efficacy of prebiotics such as fructooligosaccharides and Plantago ovata seeds in ulcerative colitis are inconclusive and the data regarding the utility of prebiotics in pouchitis is limited. The results of the clinical trials for remission induction and maintenance in active Crohn's disease or post-operative relapse with probiotics and prebiotics are inadequate and not very convincing. Prebiotics and probiotics are safe, effective and have great therapeutic potential. However, better designed clinical trials in the multicenter setting with a large sample and long duration of intervention are needed to identify the specific strain or combination of probiotics and prebiotics which will be more beneficial and effective in patients with inflammatory bowel disease.

scholarly journals Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis

2016 ◽  
Vol 6 (3) ◽  
pp. 164-165
Author(s):  
NS Neki ◽  
Ankur Jain
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Adverse Effects ◽  
Bowel Disease ◽  
Modifying Agent ◽  
Immune Mediated ◽  
Established Disease ◽  
Inflammatory Bowel ◽  
Disease Modifying

Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.J Enam Med Col 2016; 6(3): 164-165

Does Colonoscopy by a Skilled Endoscopist Cause Any Adverse Effects in Quiescent Ulcerative Colitis Patients? A Case-control Study

2010 ◽  
Vol 44 (10) ◽  
pp. 720-722
Author(s):  
Morio Takahashi ◽  
Yasumi Katayama ◽  
Kazuyoshi Suzuki ◽  
Kazuto Koizumi ◽  
Koji Nishida ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Adverse Effects ◽  
Case Control Study ◽  
Case Control ◽  
Control Study

P-085 Adverse Effects on Renal Function in Long-Term Use of Tacrolimus for Ulcerative Colitis Patients

2016 ◽  
Vol 22 ◽  
pp. S36
Author(s):  
Fumihiko Iwamoto ◽  
Masakazu Nagahori ◽  
Maiko Kimura ◽  
Kento Takenaka ◽  
Toshimitsu Fujii ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Renal Function ◽  
Adverse Effects

scholarly journals P577 Withdrawal of thiopurines in patients with Ulcerative Colitis in remission

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S534-S534
Author(s):  
C Amor Costa ◽  
C Suárez Ferrer ◽  
J Poza Cordón ◽  
J L Rueda García ◽  
M Sánchez Azofra ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ulcerative Colitis ◽  
Standard Deviation ◽  
Adverse Effects ◽  
Medical Decision ◽  
Concomitant Treatment ◽  
Duration Of Treatment ◽  
The Mean ◽  
Time To Relapse

Abstract Background Thiopurines (TP) are widely used in monotherapy in patients with ulcerative colitis (UC), mainly for the maintenance of remission in case of corticodependence or corticoresistance after cyclosporine use. However, these are drugs with significant side effects, especially in the long term. The optimal duration of treatment with TP remains unknown, so it is important to determine the risk factors for relapse in order to identify the group of patients in which treatment can be withdrawn. Methods A retrospective study was performed. Patients with UC in remission, in maintenance treatment with TP, who had discontinued the drug due to either maintained remission or the onset of adverse effects were included. Results 26 patients were included, 1 with proctitis, 9 with left colitis and 16 with pancolitis. 24 (92.31%) were treated with azathioprine and 2 (7.69%) with mercaptopurine. The mean treatment time with TP was 68.09 months (standard deviation 56.65). 11 patients (42.31%) discontinued TP due to adverse effects and the remaining patients (57.69%) discontinued it by medical decision because they were in prolonged remission. After withdrawal of TP, 92.34% of patients continued treatment with mesalazine and the remaining 7.69% without concomitant treatment. During follow-up, 10 patients (38.4%) relapsed and 16 patients (61.53%) had no relapse until the end of follow-up. The mean time from TP withdrawal to the onset of relapse was 69.15 months (standard deviation 52.53). Of the 10 patients who presented a flare, 5 (50%) were controlled by optimizing the dose of mesalazine, 4 (40%) required the addition of oral corticosteroids and 1 (10%) required biologics. No significant differences were found when comparing the time to relapse if the reason for discontinuation of TP was having had an adverse effect (65.05 months) or maintained remission (79.79 months) (p=0.42). No statistically significant differences were found in time to relapse when comparing time on TP treatment, presence of concomitant treatment with mesalazine or active smoking. Conclusion One third of patients relapsed after TP withdrawal. Discontinuation of TP in patients with UC in remission should be individualized according to the patient’s risk factors, the indication and the duration of treatment.

scholarly journals Successful Long-Term Use of Infliximab in Refractory Pouchitis in an Adolescent

2010 ◽  
Vol 2010 ◽  
pp. 1-4 ◽  
Author(s):  
Jessica Yeates ◽  
Mohsin Rashid
Keyword(s):  
Ulcerative Colitis ◽  
Adverse Effects ◽  
Maintenance Therapy ◽  
Ileal Pouch ◽  
Ileal Pouch Anal Anastomosis ◽  
Common Complication ◽  
Anal Anastomosis ◽  
Permanent Ileostomy ◽  
Inflammatory Drugs

Pouchitis is a common complication that develops after an ileal pouch-anal anastomosis after colectomy for ulcerative colitis. In some cases, pouchitis becomes chronic and refractory to conventional therapies including antibiotics, corticosteroids, immunomodulators, probiotics, and anti-inflammatory drugs. We report a case of an adolescent with chronic pouchitis who not only improved with infliximab therapy but remains in long-term remission with maintenance therapy without any adverse effects. Infliximab is a safe and effective therapy for refractory pouchitis and may obviate the need for pouch removal and a permanent ileostomy.

Melatonin for the treatment of gastrointestinal disorders: an overview

2021 ◽  
Vol 19 (3) ◽  
pp. 18-22
Author(s):  
David Mantle ◽  
Marcel G Smits
Keyword(s):  
Ulcerative Colitis ◽  
Irritable Bowel Syndrome ◽  
Adverse Effects ◽  
Reflux Disease ◽  
Therapeutic Strategies ◽  
Oesophageal Reflux ◽  
Gastrointestinal Disorders ◽  
Pharmacological Agents ◽  
Oesophageal Reflux Disease ◽  
Irritable Bowel

Conventional pharmacological agents for the treatment of common (10–25% prevalence) gastrointestinal disorders may be associated with significant adverse effects in some patients. Therefore, there is a rationale to develop alternative therapeutic strategies for such individuals. This article reviews the evidence for the use of supplemental melatonin—a substance with an excellent safety record, free of significant adverse effects—in the management of gastro-oesophageal reflux disease, gastritis, irritable bowel syndrome and ulcerative colitis.

scholarly journals A Rare Case of New-Onset Ulcerative Colitis following Initiation of Secukinumab

2019 ◽  
Vol 2019 ◽  
pp. 1-5 ◽  
Author(s):  
Ted George Achufusi ◽  
Prateek S. Harnee ◽  
Sekou Rawlins
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Monoclonal Antibody ◽  
Psoriatic Arthritis ◽  
Ankylosing Spondylitis ◽  
Adverse Effects ◽  
Rare Case ◽  
Young Male ◽  
Inflammatory Bowel ◽  
New Onset

Secukinumab is an IgG monoclonal antibody widely used for treatment of ankylosing spondylitis, psoriasis, and psoriatic arthritis. Recently, there has been increasing controversy regarding potential adverse effects of the drug especially in those with underlying inflammatory bowel disease. We present the case of a young male patient who developed severe new-onset ulcerative colitis following initiation of secukinumab for psoriasis, with excellent response and rapid resolution of symptoms with infliximab.

Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

2021 ◽  
pp. 247553032110295
Author(s):  
Kayla H. Taylor ◽  
Steven R. Feldman
Keyword(s):  
Ulcerative Colitis ◽  
Adverse Effects ◽  
Biologic Therapy ◽  
Biologic Therapies ◽  
Case Presentation ◽  
Inflammatory Bowel ◽  
Psoriatic Lesions ◽  
Long Term Adverse Effects ◽  
Systemic Therapies

Introduction: Anti-TNF treatment is effective for inflammatory bowel disease (IBD), however it also has the potential to cause paradoxical psoriasis which can be challenging to manage. Discontinuation of anti-TNF agents may improve psoriatic lesions but may worsen IBD. Combining biologic therapies, though not yet commonly practiced, may be a useful approach to the treatment of both conditions. Case Presentation: We describe a case of paradoxical palmoplantar psoriasis in a 48-year-old woman with ulcerative colitis (UC). Her UC was well-managed on infliximab. Following trials of several other topical and systemic therapies for her psoriatic lesions, she ultimately received relief on combined ustekinumab and infliximab therapy without flare of her IBD. Discussion: While other publications report success using ustekinumab for paradoxical psoriasis following cessation of infliximab, this case report highlights successful treatment using a combination of ustekinumab and infliximab with no reported adverse effects at 3 months. Conclusion: Discontinuation of the anti-TNF agent and use of a single biologic that may treat both IBD and psoriasis is a treatment option. Additionally, combining biologic therapies, though not yet commonly practiced, may be a useful, albeit costly, approach to prevent potential flares of IBD that may accompany cessation of some biologics. Further studies may be beneficial to assess for long term adverse effects.

Sign in / Sign up

Export Citation Format

Share Document